Miroslav Kosar

Miroslav Kosar

Auto-generated profile, based on publicly available information

Miroslav Kosar

ETH Zurich

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2023 in ChemRxiv
Verified
Preprint
Open access
PDF file
ECErick Moran Carreira
Erick Moran Carreira
MKMiroslav Kosar
Miroslav Kosar
RSRoman Sarott
Roman Sarott
DSDavid Sykes
David Sykes
AVAlexander Viray
Alexander Viray
Uwe GretherUwe Grether
Uwe Grether
We report the structure-based design of cannabinoid receptor type 2 (CB2R)-selective inverse agonists (S)-1 and (R)-1, which were derived from privileged agonist HU-308 by introduction of a phenyl group at the gem-dimethylheptyl sidechain. Epimer (R)-1 exhibits high affinity for CB2R with Kd = 39 nM and serves as a platform for the synthesis of a wide variety of probes. Notably, the fluorescent probes, for the first time, retain their inverse agonist functionality, high affinity, and selectivity for CB2R independent of linker and fluorophore substitution. Ligands (S)-1, (R)-1, and their derivatives act as inverse agonists in CB2R-mediated cAMP as well as G protein recruitment assays, and do not trigger β-arrestin–receptor association. Furthermore, no receptor activation was detected in live cell ERK1/2 phosphorylation and Ca2+-release assays. Confocal fluorescence imaging experiments with (R)-7 (Alexa488) and (R)-9 (Alexa647) probes employing BV-2 microglial cells visualized CB2R expressed at endogenous levels. Finally, molecular dynamics simulations corroborate the initial docking data in which inverse agonists restrict movement of toggle switch, Trp2586.48, and thereby stabilize CB2R in its inactive state. The present study serves as a blueprint for the rational design of GPCR ligands beyond CB2R with a tailored functional response.

22 December 2022 in ChemRxiv
Verified
Preprint
Open access
PDF file
ECErick Moran Carreira
Erick Moran Carreira
MKMiroslav Kosar
Miroslav Kosar
DSDavid Sykes
David Sykes
AVAlexander Viray
Alexander Viray
RVRosa Maria Vitale
Rosa Maria Vitale
DVDmitry Veprintsev
Dmitry Veprintsev
Pharmacological modulation of cannabinoid receptor type 2 (CB2R) holds promise for the treatment of neuroinflammatory disorders, such as Alzheimer’s disease. Despite the importance of CB2R, its expression and downstream signaling are insufficiently understood in disease- and tissue-specific con-texts. Ligand-directed covalent (LDC) labeling enables the study of endogenously expressed proteins in living cells, tissues, and animals without impairment of native protein function. Herein, we employed in silico docking and molecular dynamics simulations to evaluate feasibility of LDC labeling of CB2R and guide design of LDC probes. We demonstrate selective, covalent labeling of a peripheral lysine residue of CB2R by exploiting fluorogenic O-nitrobenzoxadiazole (O-NBD) functionalized probes in a TR-FRET as-say. The rapid proof-of-concept verification with O-NBD probes inspired incorporation of advanced elec-trophiles suitable for experiments in live cells. To this end, novel synthetic strategies towards N-sulfonyl pyridone and N-acyl-N-alkyl sulfonamide LDC probes were developed, which allowed covalent delivery of fluorophores suitable for cellular experiments. The LDC probes were characterized in vitro by a radi-oligand binding assay and TR-FRET experiments. Application of the LDC probes in flow cytometry, imag-ing flow cytometry, and confocal fluorescence microscopy confirmed specific labeling of CB2R in live cells.